Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 26 04:00PM ET
11.10
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-13.72 Insider Own75.74% Shs Outstand1.08M Perf Week-23.61%
Market Cap27.75M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.61M Perf Month-14.82%
Income-14.80M PEG- EPS next Q- Inst Own5.76% Short Float0.74% Perf Quarter-17.81%
Sales0.14M P/S198.21 EPS this Y- Inst Trans- Short Ratio1.17 Perf Half Y-58.47%
Book/sh5.07 P/B2.19 EPS next Y- ROA-194.70% Short Interest0.00M Perf Year-51.56%
Cash/sh0.14 P/C81.62 EPS next 5Y- ROE- 52W Range10.90 - 35.17 Perf YTD-18.02%
Dividend Est.- P/FCF- EPS past 5Y-12.67% ROI-240.23% 52W High-68.44% Beta1.17
Dividend TTM- Quick Ratio0.13 Sales past 5Y-39.80% Gross Margin-20.42% 52W Low1.81% ATR (14)2.58
Dividend Ex-Date- Current Ratio0.13 EPS Y/Y TTM-41.47% Oper. Margin-7014.08% RSI (14)41.06 Volatility12.79% 20.71%
Employees4 Debt/Eq0.80 Sales Y/Y TTM317.65% Profit Margin-10424.65% Recom- Target Price-
Option/ShortNo / No LT Debt/Eq0.13 EPS Q/Q-27.85% Payout- Rel Volume0.00 Prev Close11.10
Sales Surprise- EPS Surprise- Sales Q/Q600.00% EarningsNov 14 AMC Avg Volume3.87K Price11.10
SMA20-22.16% SMA50-20.62% SMA200-44.79% Trades Volume0 Change0.00%
Mar-22-24 05:27PM
Nov-17-23 08:00AM
Nov-14-23 04:05PM
Aug-30-23 07:00AM
Aug-14-23 04:05PM
06:28PM Loading…
Jul-24-23 06:28PM
Jul-21-23 05:32PM
May-23-23 04:05PM
May-12-23 04:05PM
Apr-26-23 04:05PM
Mar-31-23 04:05PM
Nov-25-22 03:41PM
Nov-10-22 04:05PM
Aug-12-22 04:05PM
May-18-22 08:30AM
04:05PM Loading…
May-13-22 04:05PM
Mar-29-22 04:05PM
Dec-14-21 08:30AM
Nov-30-21 08:30AM
Nov-23-21 04:05PM
Nov-12-21 04:05PM
Aug-13-21 04:05PM
Jul-23-21 04:15PM
May-17-21 04:05PM
Mar-31-21 04:05PM
Mar-12-21 08:00AM
Mar-10-21 08:00AM
Mar-02-21 08:00AM
Feb-02-21 11:24PM
Dec-22-20 03:08PM
04:13PM Loading…
Nov-27-20 04:13PM
Nov-16-20 04:05PM
Oct-28-20 08:00AM
Sep-15-20 07:59AM
Sep-09-20 08:00AM
08:00AM
Aug-14-20 04:05PM
Aug-07-20 07:02AM
Jun-16-20 08:00AM
Jun-05-20 04:15PM
Jun-02-20 08:00AM
May-29-20 08:00AM
May-21-20 08:30AM
May-14-20 04:05PM
May-01-20 08:54AM
Mar-30-20 05:40PM
Mar-20-20 09:00AM
Feb-28-20 08:00AM
Feb-09-20 09:12AM
Feb-03-20 08:00AM
Jan-29-20 08:00AM
Jan-14-20 08:00AM
Dec-26-19 08:00AM
Dec-10-19 08:00AM
08:00AM
Dec-09-19 07:00AM
Nov-14-19 04:00PM
Nov-13-19 09:50AM
Nov-11-19 05:28AM
Nov-08-19 06:58PM
Oct-30-19 08:00AM
Oct-11-19 08:00AM
Sep-10-19 08:00AM
Sep-09-19 07:00AM
Sep-04-19 08:00AM
Aug-14-19 05:16PM
Aug-05-19 05:14PM
Jul-09-19 08:00AM
May-15-19 04:05PM
May-01-19 08:00AM
Apr-05-19 08:00AM
Apr-01-19 04:48PM
Mar-22-19 07:00AM
Mar-21-19 07:00AM
Mar-07-19 07:00AM
Feb-14-19 08:00AM
Jan-31-19 08:00AM
Jan-22-19 08:00AM
Jan-10-19 08:00AM
Jan-09-19 08:00AM
Jan-04-19 08:00AM
Jan-02-19 07:00AM
AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.